by Claire | Oct 23, 2022 | Uncategorized
DIADEM PRESENTS DATA AT 22ND INTERNATIONAL CONFERENCE ON ALZHEIMER’S DRUG DISCOVERY HIGHLIGHTING ITS BLOOD-BASED BIOMARKER TEST IS 84% CONCORDANT WITH AMYLOID BRAIN IMAGING —Further Analysis of Clinical Validation Data Shows Diadem’s AlzoSure® Predict Is Highly...
by Claire | Oct 23, 2022 | Uncategorized
EUROPEAN INVESTMENT BANK TO PROVIDE A €7.5 MILLION LOAN TO SUPPORT FURTHER RESEARCH AND DEVELOPMENT OF DIADEM’S ALZOSURE® PREDICT BLOOD TEST FOR ALZHEIMER’S DISEASE • First CE-IVD-marked blood test that predicts likely progression to Alzheimer’s disease up to six...
by Claire | Oct 23, 2022 | Uncategorized
DIADEM ANNOUNCES FIRST CLOSING OF €10 MILLION EQUITY FINANCING FOR ITS ALZOSURE® PREDICT PROGNOSTIC BLOOD TEST FOR ALZHEIMER’S DISEASE —CDP Venture Capital and Panakès Partners Leading Equity Financing in Association with Recent €7.5M European Investment Bank Venture...
by Claire | Oct 23, 2022 | Uncategorized
DIADEM RECEIVES CE-IVD CERTIFICATION TO MARKET ITS ALZOSURE® PREDICT PROGNOSTIC BLOOD TEST FOR THE EARLY PREDICTION OF ALZHEIMER’S DISEASE IN EUROPE —First Approved Blood Test that Can Predict Likely Progression to Alzheimer’s Disease Up to Six Years in Advance—...
by Claire | Oct 23, 2022 | Uncategorized
PRESENTATION AT CLINICAL TRIALS ON ALZHEIMER’S DISEASE MEETING HIGHLIGHTS HOW DIADEM’S ALZOSURE® PREDICT CAN ENABLE AD CLINICAL TRIALS AND SCREENING FOR EARLY DETECTION OF AD —Longitudinal Analyses Show AlzoSure® Predict Identifies Individuals Who Will Progress to...
by Claire | Oct 23, 2022 | Uncategorized
FDA GRANTS BREAKTHROUGH DEVICE DESIGNATION TO DIADEM’S ALZOSURE® PREDICT PROGNOSTIC BLOOD TEST FOR THE EARLY PREDICTION OF ALZHEIMER’S DISEASE —First Prognostic Blood Test that Can Predict Likely Progression to Alzheimer’s Disease Up to Six Years in Advance— ...
